ARTELO BIOSCIENCES, INC.
ARTL evidence brief
What we can confirm
- Market Cap:
- $3.0M
What it means
What to watch
Prepared research question
What matters most for ARTL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ARTL
Artelo Biosciences, Inc. (Nasdaq: ARTL) is a clinical-stage biopharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, for cancer, pain, dermatological, and neurological conditions [news · published 2026-08-13].
Key risk: Pre-revenue stage
Market Cap
$3.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Artelo Biosciences, Inc. (Nasdaq: ARTL) is a clinical-stage biopharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, for cancer, pain, dermatological, and neurological conditions [news · published 2026-08-13].
- Artelo is a clinical-stage company focused on lipid-signaling modulation, including the endocannabinoid system [sec_mda · as of 2026-08-12].
- Lead candidate ART27.13 is in Phase 2 for cancer-related anorexia; interim data showed substantial weight gain and activity improvements versus placebo [news · published 2025-10-15].
- ART26.12, a first-in-class FABP5 inhibitor for persistent pain, completed a Phase 1 trial with no safety concerns and predictable linear plasma exposure [news · published 2025-10-15].
- ART12.11, a proprietary CBD:TMP cocrystal for anxiety and depression, received UK MHRA guidance for accelerated development via the Innovative Licensing and Access Pathway [news · published 2025-08-01].
- Net income was -$2.4M and shareholders' equity was $5.0M as of 2026-06-30 [sec].
What works
- Multiple pipeline candidates are advancing: ART27.13 in Phase 2 for cancer anorexia, ART26.12 completed Phase 1 for pain, and ART12.11 received MHRA guidance for anxiety/depression [news · published 2025-10-15][news · published 2025-08-01].
- ART27.13 interim Phase 2 data showed substantial weight gain and activity improvements versus placebo, suggesting potential clinical benefit [news · published 2025-10-15].
- ART26.12 Phase 1 data demonstrated no safety concerns and predictable linear plasma exposure, supporting further development [news · published 2025-10-15].
- ART12.11 was identified by the UK MHRA as a candidate for accelerated development via the Innovative Licensing and Access Pathway [news · published 2025-08-01].
What to weigh
- The company reported a net loss of $2.4M for the period ending 2026-06-30, with shareholders' equity of $5.0M [sec].
- ART27.13 faces at least one competitor (M.D. Anderson Cancer Center) in the cancer anorexia space [pipeline].
- The company is pre-revenue and relies on external funding and partnerships to advance its pipeline [news · published 2026-03-18].
From the filings
Quoted directly from source documents.
ART27.13 interim Phase 2 data showed substantial weight gain and activity improvements versus placebo
“ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and Activity Improvements in the Treated Patients versus Placebo”
News · October 15, 2025
ART26.12 Phase 1 data demonstrated no safety concerns and predictable linear plasma exposure
“ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions”
News · October 15, 2025
ART12.11 received MHRA guidance for accelerated development via the Innovative Licensing and Access Pathway
“MHRA indicated ART12.11 may be a candidate for accelerated development via the Innovative Licensing and Access Pathway”
News · August 1, 2025
Risks & what to watch (3)›
Key risks
- Pre-revenue stage — Artelo has no approved products and reported a net loss of $2.4M as of 2026-06-30, relying on external funding [sec].
- Competition in lead program — ART27.13 for cancer anorexia faces a competitor from M.D. Anderson Cancer Center [pipeline].
- Dependence on partnerships — Pipeline advancement relies on third-party funding and collaborations, e.g., the glaucoma study funded by Glaucoma UK [news · published 2026-03-18].
What to watch
- First patient enrollment in the third-party funded glaucoma study for ART27.13, anticipated in Q2 2026 [news · published 2026-03-18].
- Upcoming clinical data readouts for ART27.13 Phase 2 and potential initiation of Phase 1 for ART12.11 [news · published 2026-08-13].
- Financial sustainability given net loss of $2.4M and shareholders' equity of $5.0M as of 2026-06-30 [sec].
Sources: News · Pipeline · SEC MD&A · Generated October 5, 2026 · How we verify sources →
Run ARTELO BIOSCIENCES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ARTELO BIOSCIENCES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
10
Total value held
$346K
| Holder | Shares | Value |
|---|---|---|
| kathmere capital management, llc | 13,250 | $100K |
| jane street group, llc | 13,079 | $99K |
| vanguard capital management llc | 10,129 | $77K |
| vanguard fiduciary trust co | 3,139 | $24K |
| citigroup inc | 3,076 | $23K |
| tower research capital llc (trc) | 2,826 | $21K |
| clear street group inc. | 100 | $758 |
| rothschild investment llc | 2 | $15 |
| cwm, llc | 1 | $8 |
| osaic holdings, inc. | 1 | $7 |
Short Interest
as of May 20, 2026- % of float
- 6.7%
- Days to cover
- 0.0
- Shares short
- 62,523
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ARTL short interestGovernance
Frequently asked questions
What is the AI investment thesis for ARTELO BIOSCIENCES, INC.?
Artelo Biosciences, Inc. (Nasdaq: ARTL) is a clinical-stage biopharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, for cancer, pain, dermatological, and neurological conditions [news · published 2026-08-13].
Who is the CEO of ARTELO BIOSCIENCES, INC.?
Mr. Gregory D. Gorgas M.B.A. is the chief executive officer of ARTELO BIOSCIENCES, INC. (ARTL).
Where is ARTELO BIOSCIENCES, INC. headquartered?
ARTELO BIOSCIENCES, INC. (ARTL) is headquartered in Solana Beach, CA, United States.
What therapeutic areas does ARTELO BIOSCIENCES, INC. focus on?
ARTELO BIOSCIENCES, INC. develops therapies across Oncology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.